Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Ophthalmological Medicine
Volume 2017, Article ID 5036248, 5 pages
https://doi.org/10.1155/2017/5036248
Case Report

Intravitreal Ziv-Aflibercept in Treatment of Naïve Chronic Central Serous Chorioretinopathy Related Choroidal Neovascular Membrane

Shri Ganesh Vinayak Eye Hospital, Raipur, India

Correspondence should be addressed to Charudutt Kalamkar; ni.oc.oohay@30ttudurahc

Received 30 March 2017; Revised 5 May 2017; Accepted 7 November 2017; Published 23 November 2017

Academic Editor: Pradeep Venkatesh

Copyright © 2017 Nishant Radke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. R. Guyer, L. A. Yannuzzi, J. S. Slakter, J. A. Sorenson, A. Ho, and D. Orlock, “Digital indocyanine green videoangiography of central serous chorioretinopathy,” JAMA Ophtalmology, vol. 112, no. 8, pp. 1057–1062, 1994. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Iida, S. Kishi, N. Hagimura, and K. Shimizu, “Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy,” Retina, vol. 19, no. 6, pp. 508–512, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. F. M. Penha, F. B. Aggio, and P. P. Bonomo, “Severe Retinal Thermal Injury After Indocyanine Green-Mediated Photothrombosis for Central Serous Chorioretinopathy,” American Journal of Ophthalmology, vol. 143, no. 5, pp. 887–889, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Ünlü, G. Erdogan, T. Aydogan et al., “Intravitreal bevacizumab for treatment of central serous chorioretinopathy,” Journal of Ophthalmic & Vision Research, vol. 11, no. 1, pp. 61–65, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Inoue, K. Kadonosono, Y. Watanabe, S. Kobayashi, S. Yamane, and A. Arakawa, “Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy,” Ophthalmologica, vol. 225, no. 1, pp. 37–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Papadopoulos, J. Martin, Q. Ruan et al., “Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab,” Angiogenesis, vol. 15, no. 2, pp. 171–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Chhablani, R. Narayanan, A. Mathai, R. Yogi, and M. Stewart, “Short-term safety profile of Intravitreal Ziv-Aflibercept,” Retina, vol. 36, no. 6, pp. 1126–1131, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Chhablani, F. Pichi, R. Silva et al., “Antiangiogenics in Choroidal Neovascularization associated with laser in central serous Chorioretinopathy,” Retina, vol. 36, no. 5, pp. 901–908, 2016. View at Publisher · View at Google Scholar · View at Scopus